Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity

Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity

Bourque M; Liu B; Dluzen D E; Di Paolo T

Biochemical Pharmacology

2007

2007-11

The selective estrogen receptor modulator tamoxifen and estradiol were shown to protect nigrostriatal dopamine concentration loss by methamphetamine in female mice whereas male mice were protected only by tamoxifen. The present study examined the protective properties of tarnoxifen in male mice on several nigrostriatal dopaminergic markers and body temperature. Intact male mice were administered 12.5 or 50 mu g tarnoxifen 24 h before methamphetamine treatment. Basal body temperatures of male mice remained unchanged by the tarnoxifen treatment. Methamphetamine reduced striatal dopamine and its metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid concentrations, striatal and substantia nigra dopamine and vesicular monoamine transporter specific binding as well substantia nigra dopamine and vesicular monoamine transporter mRNA levels and increased striatal preproenkephalin mRNA levels. These methamphetamine effects were not altered by 12.5 mu g tarnoxifen except for increased striatal dopamine metabolites and turnover. Tamoxifen at 50 mu g reduced the methamphetamine effect on striatal dopamine concentration, dopamine transporter specific binding and prevented the increase in preproenkephalin mRNA levels; in the substantia nigra tamoxifen prevented the decrease of dopamine transporter mRNA levels. The present results show a tamoxifen dose-dependent prevention of loss of various dopaminergic markers against methamphetamine-induced toxicity in male mice. Since this is the only known hormonal protection of male mice against methamphetamine toxicity, these findings provide important new information on specific parameters of nigrostriatal dopaminergic function preserved by tarnoxifen. (C) 2007 Published by Elsevier Inc.

disease; Pharmacology & Pharmacy; microglial activation; parkinsons-disease; Substantia nigra; messenger-rna; dopamine; transporter; neurotoxicity; Neuroprotection; estrogen-receptor-alpha; induced; striatum; gender-differences; estradiol; Parkinson's; striatal tissue fragments; Substantia nigra

Journal Article or Conference Abstract Publication

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1413-1423

9

74